Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Mar 10;11:5558. doi: 10.1038/s41598-021-84840-3

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Convalescent plasma from COVID-19-recovered subjects inhibits cell–cell fusion mediated by the S-ACE2 interactions. (a) The effector cells: non-S-transfected 293 T (EGFP-alone), SARS-CoV-S-transfected 293 T, SARS-CoV-2-S-transfected 293 T, or SARS-CoV-2-S-transfected 293 T cells were incubated with 10% COVID-19 S2 plasma. SARS-CoV-2-S-transfected 293 T cells with 10% COVID-19 S3 plasma were incubated with the ACE2/293 T target cells for 4 h with 80 ng/ml of trypsin-DMEM (upper panel) or 10% FBS-DMEM (lower panel). (b) Plasma from Influenza-recovered subject cannot inhibit cell–cell fusion mediated by the S-ACE2 interactions. (c) The number of cell–cell fusions induced by SARS-CoV-S, SARS-CoV-2-S, and SARS-CoV-2-S following pre-incubated with 10% COVID-19 S2, S3, S21, S23, S30 or F2 plasma are shown (*P < 0.05, **P < 0.01, and ***P < 0.001, respectively; the numbers on top of the bars represent the inhibition extent percentiles of S/ACE2 interaction of the convalescent plasma). d) The correlation between the inhibition extent of S1/ACE2 interaction and the number of fusing cells per field were shown. The graphs in c and d were created by Prism 6.01 software (https://www.graphpad.com/).